Purified Equine Anti-snake Venom Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is released as a lyophilised or frozen-liquor active pharmaceutical ingredient of equine origin. The representative model designation PEAV-F(ab′)2-45 identifies a nominal 45 g/L protein concentrate processed to remove Fc fragments and non-immunoglobulin plasma proteins. It is supplied as a sterile-filtered concentrate for aseptic dilution into parenteral solutions, or as a spray-dried/lyophilised intermediate for dry blending into granules, capsules, and coated-tablet cores. The API is manufactured from pooled equine plasma obtained from donor horses hyperimmunised against geographically defined venom pools; the immunisation schedule and venoms used in the antigenic challenge are lot-specific and are declared on the certificate of analysis. The material is not a crude antiserum. The manufacturing sequence includes caprylic acid precipitation of bulk plasma proteins, pepsin digestion under controlled pH and temperature, anion-exchange chromatography, and tangential-flow diafiltration. Each step is selected to preserve neutralising antibody fragments while reducing albumin, complement components, and other horse serum proteins that contribute to acute hypersensitivity reactions. The injectable and dry presentations are intended for licensed veterinary compounding or downstream formulation by a marketing authorisation holder.

Purified F(ab′)₂ Production From Equine Hyperimmune Plasma

The hyperimmune plasma is clarified by continuous-disc stack centrifugation, followed by caprylic acid addition at room temperature to precipitate non-immunoglobulin proteins. The supernatant is pH-adjusted to pH 3.2–3.5 and digested with porcine pepsin; the reaction is quenched by raising pH to 7.0 and cooling to 4 °C. The resulting F(ab′)₂ fragment has a molecular weight of approximately 100 kDa, compared with 150 kDa intact IgG. Removal of the Fc region reduces binding to complement receptors and Fcγ receptors, which has been associated with reduced complement activation and lower incidence of early adverse reactions in clinical antivenom use. The digest is purified by depth filtration and anion-exchange chromatography, then concentrated and diafiltered against pH 6.0–7.0 phosphate-glycine buffer using 30 kDa MWCO polyethersulfone tangential-flow membranes. The membrane skid is operated at a transmembrane pressure of 1.0–1.5 bar and a feed flow of 4–6 L/min per 0.5 m² cassette, with retentate temperature maintained below 15 °C to limit aggregate formation. This purification strategy is consistent with WHO TRS 1004, Annex 5, for snake antivenom immunoglobulins. In-process identity is confirmed by immunoelectrophoresis against the target venoms, while fragment distribution is monitored by size-exclusion HPLC using Ph. Eur. 2.2.30. The product differs from whole equine IgG antivenom and crude hyperimmune serum principally because the Fc region is absent; the remaining F(ab′)₂ fragment retains the two antigen-binding sites required for venom toxin neutralisation but exhibits reduced complement-dependent effector function.

Batch-to-batch variability observed on production lines arises mainly from donor horse neutralising titre and from pepsin digestion endpoint. When digestion time is extended beyond 90 min, F(ab′)₂ converts to Fab fragments and neutralising potency declines. Conversely, incomplete digestion leaves intact IgG and purified product with higher Fc-related complement activation. The manufacturing control therefore includes in-process SEC-HPLC at the digestion step and after chromatography; the target fragment purity is ≥90% F(ab′)₂ with ≤5% high-molecular-weight aggregate. Protein A affinity chromatography is avoided in this train because F(ab′)₂ lacks the Fc region and would not bind, while anion-exchange at pH 5.8 removes residual pepsin and acidic glycoproteins. Residual moisture in the lyophilised cake is maintained below 2.5% by Karl Fischer titration per Ph. Eur. 2.5.12 to preserve fragment integrity during storage at 2–8 °C. The spray-dried or lyophilised intermediate is milled and sieved through 150 µm stainless-steel mesh for granulation, but milling increases amorphous surface area and can increase moisture uptake in environments above 60% RH. For dry presentations, the API is blended with cryoprotectant or stabiliser only after sieving; direct blending of unmilled cake produces poor content uniformity, as observed on twin-shell blenders running below 15 rpm and on bin blenders with IBC fill volumes above 70% of rated capacity.

What Limits Oral Bioavailability When the API Is Granulated or Encapsulated?

Although the product is designated for tablets, capsules, powders, granules, and premix, the intrinsic physicochemical properties of F(ab′)₂ place strict boundaries on non-injectable presentations. Equine F(ab′)₂ is susceptible to pepsin and trypsin. In the stomach of monogastric species, pH below 3.5 and pepsin cause rapid cleavage into inactive fragments; in the intestinal lumen, pancreatic trypsin and chymotrypsin further degrade the molecule. Therefore, simple tablets, capsules, powders, granules, and feed premixes that release the API in the gastric phase are not suitable for systemic snake envenomation treatment. If a dry oral presentation is formulated, a gastro-resistant or enteric-coated multiparticulate system is required. The coating threshold is formulation-specific but must withstand pH 1.2 for a minimum of 120 min according to the delayed-release criteria described in Ph. Eur. 2.9.3 or USP 711, followed by release at pH 6.8. Published data for this specific configuration are limited; consequently, the API is supplied for injectable reconstitution as the primary licensed use, with dry forms intended for formulation development or for localised oral neutralisation protocols where available clinical evidence supports such use. The neutralisation assay used for injectable release does not predict systemic oral activity, because the assay bypasses gastrointestinal degradation. For capsules or tablets containing dried API, a supplementary dissolution test is required under pH conditions relevant to the target species and coating technology, and batch release documentation should state the dissolution apparatus type, rotation speed, and medium volume used.

Sterility, Endotoxin and Residual Solvent Boundaries

For solutions and injectables, the API is filtered through a 0.22 µm polyethersulfone membrane. Bulk solution is tested for sterility by membrane filtration per Ph. Eur. 2.6.1; bacterial endotoxin is measured by LAL per Ph. Eur. 2.6.14, with a limit set at <0.5 IU/mg protein for injectable grades. Residual solvents from caprylic acid precipitation and buffer exchange are controlled via gas chromatography per Ph. Eur. 2.4.24; ethanol, if used for precipitation, is limited to ≤600 ppm for veterinary parenterals unless otherwise specified by regional requirements. Preservative efficacy for multi-dose solutions is evaluated per Ph. Eur. 5.1.3 using Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans, and Aspergillus brasiliensis. For preservative-free single-use vials, no antimicrobial preservative is added, and the reconstituted solution is used within 8 h when stored at 2–8 °C. For multi-dose solutions containing m-cresol or phenol, the manufacturer must confirm preservative compatibility with F(ab′)₂ because phenolics can induce aggregation; if turbidity exceeds the batch-specific nephelometric limit, the solution should not be used. In dry premixes, preservatives are not typically included; instead, water activity is reduced below 0.4 during drying to control microbial growth. The API itself is not terminally sterilised; therefore, aseptic processing is mandatory for sterile presentations, and the bulk solution must be sterilised by filtration immediately before filling.

When Lyophilised API Is Reconstituted for Injectable Veterinary Solutions

The lyophilised cake is reconstituted with water for injection or sodium chloride 0.9% at 15–25 °C. The vial is swirled, not shaken, to avoid foaming and shear-induced aggregation. Reconstitution time is typically less than 10 min for a 10 g protein cake when diluted to 50 mL; residual undissolved particles indicate aggregate formation or incomplete lyophilisation. The reconstituted solution is then transferred through a 5 µm glass-fibre prefilter and a 0.22 µm sterilising-grade membrane into a sterile hold vessel under laminar flow. For automated filling lines, peristaltic pumps with low-shear heads are used; rotary piston pumps can generate local heating and protein aggregation. The filling line is thermally controlled at 2–8 °C, and dissolved oxygen in the bulk solution is maintained below 2 ppm by nitrogen overlay because equine F(ab′)₂ contains methionine residues sensitive to oxidation. Sterile filtration is performed after addition of diluent and before filling; filter integrity testing is performed before and after use per ASTM F838-20 or manufacturer bubble-point specifications. The filled solution is inspected for subvisible particles using Ph. Eur. 2.9.19; the acceptance limit for particles ≥10 µm and ≥25 µm follows the parenteral monograph. For solutions intended for syringe administration, the final container is a Type I borosilicate glass vial or a cyclic olefin copolymer syringe; silicone oil in prefilled syringes should be minimised because excess silicone can promote aggregate formation in equine immunoglobulin fragments.

The API should not be combined with copper- or iron-containing vessel surfaces, as trace transition metals accelerate oxidation of histidine and methionine residues in the fragment. Long-term contact with silicone tubing is acceptable for short intervals but may extract siloxane oligomers; polypropylene or fluoropolymer contact surfaces are preferred. The freeze-dried cake is hygroscopic; exposure to relative humidity above 60% for more than 15 min during subdivision can increase residual moisture above 2.5% and reduce long-term potency. In granulation processes for dry presentations, binders such as povidone in aqueous solution should not be applied at temperatures above 40 °C, as thermal denaturation of F(ab′)₂ begins in dilute buffered conditions above 45 °C. If the API is used in aqueous film-coated multiparticulates, the inlet air temperature in fluid-bed coating is maintained below 60 °C and product temperature below 35 °C; above this range, aggregate formation increases sharply. These limits are based on stability-indicating size-exclusion data and are not generic recommendations. Avoid combination with amine-based additives that raise pH above 7.5, because prolonged exposure under alkaline conditions accelerates deamidation of asparagine residues in the F(ab′)₂ fragment.

Potency Reconciliation Across Multiple Dosage Presentations

The neutralising potency is determined by median lethal dose protection in mice; the assay is based on mixing fixed amounts of venom with dilutions of antivenom and recording mortality over 48 h. Potency is expressed as milligram venom neutralised per millilitre or per gram of lyophilised API. F(ab′)₂ API presentations are reconciled to the same reference standard using parallel-line bioassay. For dry forms such as tablets or granules, the relevant specification includes both unit dose potency and uniformity of dosage units; however, if the dry form is intended for oral use, potency in the neutralisation assay does not predict in vivo activity because the assay bypasses gastrointestinal degradation. Therefore, batch release for any non-parenteral presentation must include a supplementary disintegration or dissolution test under pH conditions relevant to the target species and coating technology. If the dosage form is a dry powder for reconstitution, the reconstituted solution is assayed for potency after passage through the same filter type used at administration; adsorptive losses to nylon membranes can exceed 10% for low-protein formulations, whereas polyethersulfone and cellulose acetate show lower binding. For injectable multi-species veterinary use, the labelled potency must state the target venom species covered by the immunisation pool, because potency against cobra, krait, viper, and saw-scaled viper venoms is not equal within a polyvalent batch.